Leverhulme Trust
Research Project Grants
Sciences
- Award winner: Vincent Fusco
- Institution: Queen’s University Belfast
- Value: £173,435
Near field subwavelength resolution imaging in lossy inhomogeneous media
- Award winner: Anjali Goswami
- Institution: University College London
- Value: £219,910
Walking the cat back: evolutionary mechanics and modularity of felid locomotion
- Award winner: David Grainger
- Institution: University of Birmingham
- Value: £141,388
How do cells protect their genes from pervasive transcription?
- Award winner: Claire Grierson
- Institution: University of Bristol
- Value: £251,769
How plant roots cohere with soil
Tenovus
- Award winner: Edgar Hartsuiker
- Institution: Bangor University
- Value: £191,397
The role of nucleotide excision repair in providing resistance to the nucleoside analogues gemcitabine and cytarabine
Royal Society
Wolfson Research Merit Awards
Awards are worth £10,000-£30,000 a year, which is a salary enhancement.
- Award winner: Philip Gale
- Institution: University of Southampton
Small molecule lipid bilayer anion transporters for biological applications
- Award winner: Adrian Hilton
- Institution: University of Surrey
4D computer vision for real-world dynamic scene understanding
- Award winner: James Hinton
- Institution: University of Leicester
Very high-energy gamma-ray astrophysics in the UK
National Institute for Health Research
Efficacy and Mechanism Evaluation Programme
- Award winner: Robert Howard
- Institution: Institute of Psychiatry
- Value: £1,846,405
Minocycline in Alzheimer’s disease efficacy trial: the MADE trial
Health Services and Delivery Research Programme
- Award winner: Claire Goodman
- Institution: University of Hertfordshire
- Value: £715,678
Optimal NHS service delivery to care homes: a realist evaluation of the features and mechanisms that support effective working for the continuing care of older people in residential settings
In detail
Health Technology Assessment Programme
Award winner: David Price
Institution: University of Aberdeen
Value: £2,118,845
A randomised, double-blind placebo controlled trial of the effectiveness of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In the UK, it affects about 3 million people and costs the NHS £1 billion a year. Some 60 per cent of the cost of treatment relates to exacerbations of the disease. Current treatment guidelines recommend inhaled corticosteroids (ICS) to reduce exacerbations and improve lung function. The airway inflammation in COPD is relatively insensitive to the anti-inflammatory effects of ICS, even at high doses. Preclinical and pilot studies demonstrate that low-dose theophylline may make airway inflammation more sensitive to ICS; thus it could be used with ICS to reduce the rate of COPD exacerbation. The researchers will investigate whether adding low-dose theophylline to ICS treatment cuts the rate of hospitalisation with exacerbations of COPD and makes patients feel better. They will determine the clinical effectiveness and cost- effectiveness of the procedure.